NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NASDAQ · Medical Distribution · USD

DataMEDS AI, Inc. (MEDS) Stock Analysis

DataMEDS AI, Inc. (MEDS) is a Medical Distribution stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

MEDS

$2.30

−$0.42 (−15.44%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MEDS with… →

MEDS Key Statistics

As of Oct 22, 2026
Trading
Open
$2.65
Previous Close
$2.72
Day's Range
2.25–2.69
52-Week Range
0.82–73.00
Volume
886.18K
Valuation
Market Cap
$10.39M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.29
EPS (ttm)Profit attributable to each share over the last twelve months.
−46.68
Financials (FY)
Revenue (FY)
$23.34M+28.73%
Net Income (FY)
−$101.27M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.52M
1-Year Return
−87.57%
Dividend and dates
Avg Volume
6.48M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 22, 2026, MEDS closed at $2.30, −87.57% over 1 year.

DataMEDS AI, Inc. (MEDS) has a market capitalization of $10.39M.

In fiscal 2025, MEDS reported revenue of $23.34M.

MEDS Stock Return by Calendar Year

DataMEDS AI, Inc. (MEDS) return since Feb 2025: what $10,000 became

1 year
$10,000 $1,243
−87.57%
Since Feb 2025
$10,000 $121
−98.79%

If you had invested $10,000 in DataMEDS AI, Inc. (MEDS) at the close on February 21, 2025, the earliest close on record here, it would have been worth $121 at the close on October 22, 2026: −98.79% in total, −92.96% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−88.50%
2025 (partial year)−89.50%

As of October 22, 2026.

MEDS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$23.34M−$101.27M−433.9%
2024$18.13M−$6.86M−37.8%
2023$0.00−$2.90M—
2022$32.78M−$2.74M−8.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$23.34M−$6.43M−$81.19M−$101.27M−433.9%
2024$18.13M$1.77M−$6.15M−$6.86M−37.8%
2023$0.00$0.00−$2.88M−$2.90M—
2022$32.78M$5.75M−$3.42M−$2.74M−8.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MEDS Valuation vs Medical Distribution Median

Median of 11 stocks
MetricMEDSMedical Distribution medianvs median
P/S ratio1.290.353.7x the median

Medians across 11 Medical Distribution stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 22, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

DataMEDS AI, Inc. (MEDS) is capitalised at $10.39M on the latest close. The company sits in the Healthcare sector, in the Medical Distribution industry.

MEDS last closed at $2.30 on October 22, 2026. That is −$0.42 (−15.44%) against the previous close. The 52-week range on file runs from $0.82 to $73.00. The latest close sits 179.47% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $23.34M. Against the prior fiscal year total of $18.13M, that is a change of +28.73%. The same year closed with a net loss of $101.27M. Trailing earnings per share are −46.68.

Across the 4 fiscal years on file, revenue moves from $32.78M in 2022 to $23.34M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 1.29. On price-to-sales that is 3.7 times the Medical Distribution median of 0.35. The medians here are taken across 11 Medical Distribution companies that report the metric.

Annualized volatility over the trailing 1 year is 387.83%. Over the trailing twelve months the total return is −87.57%. The stored price history starts on February 21, 2025, and the total return since then is −98.79%.

Growth & Income

No dividend is on file for MEDS.

2026 is still running; the total return is −88.50% year to date.

Peer Comparison

DataMEDS AI, Inc. (MEDS) operates in the Medical Distribution industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
DataMEDS AI, Inc. MEDS $10.39M —
McKesson Corporation MCK $118.03B 27.1
Cencora, Inc. COR $64.59B 25.1
Cardinal Health, Inc. CAH $58.83B 35.1

The Medical Distribution industry average P/E ratio is 26.1x. DataMEDS AI, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Medical Distribution Stocks

MCK

McKesson Corporation

$118.03B

 COR

Cencora, Inc.

$64.59B

 CAH

Cardinal Health, Inc.

$58.83B

 HSIC

Henry Schein, Inc.

$9.58B

 AHG

Akso Health Group

$1.05B

 FOCL

EDAP TMS S.A.

$195.95M
View all Medical Distribution stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About DataMEDS AI, Inc.

DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidiary develops and delivers a portfolio of products to guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. In addition, the company develops and provides functional precision medicine oncology platform. The company was formerly known as Wellgistics Health, Inc. and changed its name to DataMEDS AI, Inc. in July 2026. DataMEDS AI, Inc. was incorporated in 2022 and is based in Tampa, Florida.

Visit website →